NCT03879629View on ClinicalTrials.gov

Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

August 21, 2019

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2027

Conditions
Breast Cancer
Interventions
DRUG

Carvedilol

oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day

Trial Locations (5)

32224

Mayo Clinic in Florida, Jacksonville

55905

Mayo Clinic in Rochester, Rochester

63110

Washington University in St. Louis, St Louis

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic, Phoenix

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Miami Heart Research Institute

UNKNOWN

lead

Mayo Clinic

OTHER

NCT03879629 - Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure | Biotech Hunter | Biotech Hunter